Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibitmetabolic stability to peptidases and excellent cellular permeation

Citation
Os. Gudmundsson et al., Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibitmetabolic stability to peptidases and excellent cellular permeation, PHARM RES, 16(1), 1999, pp. 16-23
Citations number
26
Categorie Soggetti
Pharmacology & Toxicology
Journal title
PHARMACEUTICAL RESEARCH
ISSN journal
07248741 → ACNP
Volume
16
Issue
1
Year of publication
1999
Pages
16 - 23
Database
ISI
SICI code
0724-8741(199901)16:1<16:PACPOO>2.0.ZU;2-P
Abstract
Purpose, To evaluate the cellular permeation characteristics and the chemic al and enzymatic stability of phenylpropionic acid-based cyclic prodrugs (1 ) under bar and (2) under bar of opioid peptides [Leu(5)]-enkephalin (H-Tyr -Gly-Gly-Phe-Leu-OH) and DADLE (H-Tyr-D-Ala-Gly-Phe-D-Leu-OH), respectively . Methods, The rates of conversion of cyclic prodrugs (1) under bar and (2) u nder bar to [Leu(5)]-enkephalin and DADLE, respectively, in HBSS, pH 7.4 (C aco-2 cell transport buffer) and in various biological media having measura ble esterase activity were determined by HPLC. The cell permeation characte ristics of [Leu(5)]-enkephalin, DADLE, and cyclic prodrugs (1) under bar an d (2) under bar were measured using Caco-2 cell monolayers grown onto micro porus membranes and monitored by HPLC. Results. In HBSS. pH 7.4, cyclic prodrugs (1) under bar and (2) under bar d egraded to [Leu(5)]-enkephalin and DADLE, respectively, in stoichiometric a mounts. In 90% human plasma, the rates of disappearance of cyclic prodrugs (1) under bar and 2 Were slightly faster than in HBSS, pH 7.4. These accele rated rates of disappearance in 90% human plasma could be reduced to the ra tes observed in HBSS. pH 7.4. by pretreatment of the plasma with paraoxon, a known inhibitor of serine-dependent esterases. In homogenates nates of Ca co-2 cells and rat liver, accelerated rates of disappearance of cyclic prod rugs (1) under bar and (2) under bar were not observed. When applied to the AP side of a Caco-2 cell monolayer, cyclic prodrug (1) under bar exhibited significantly greater stability against peptidase metabolism than did [Leu (5)]-enkephalin. Cyclic prodrug (2) under bar and DADLE exhibited stability similar to prodrug (1) under bar when applied to the AP side of the Caco-2 cell monolayers. Prodrug (1) under bar was 1680 fold more able to permeate the Caco-2 cell monolayers than was [Leu5]-enkephalin, in part because of its increased enzymatic stability. Prodrug (2) under bar was shown to be ap proximately 77 fold more able to permeate a Caco-2 cell monolayer than was DADLE. Conclusions. Cyclic prodrugs (1) under bar and (2) under bar, prepared with the phenylpropionic acid promoiety, were substantially more able to permea te Caco-2 cell monolayers than were the corresponding opioid peptides. Prod rug (1) under bar exhibited increased stability to peptidase metabolism com pared to [Leu(5)]-enkephalin. In 90% human plasma but not in Caco-2 cell an d rat liver homogenates, the opioid peptides were released from the cyclic prodrugs by an esterase-catalyzed reaction that is sensitive to paraoxon in hibition. However, the rate of this bioconversion appears to be extremely s low.